- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
7 Drugs Approved for Primary Care: Q2 2024
As another quarter rounds out, a new batch of drugs have been approved by the US Food and Drug Administration for conditions often seen in primary care - quite a few of them first-in-class or novel in another way. For example, the first and only pneumococcal vaccine formulated specifically to protect adults 50 years and older; the first mRNA vaccine against RSV for adults aged 60 years and older; and the first inhaled product with a novel mechanism of action approved for maintenance chronic obstructive pulmonary disease (COPD) treatment in over 20 years. In the slides below, we recap these drugs and 5 more.
Missed last quarter's drug roundup? Check out 7 Drugs Approved for Primary Care: Q1 2024
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
September 30th 2025The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.
